Entera Stock Valuation

ENTX
 Stock
  

USD 1.77  0.05  2.75%   

Do you wonder what the value of Entera Bio is? Calculating the true value of any business is not as easy as it may seem. While the market cap of a public entity, such as Entera Bio, is its stock price multiplied by the total number of shares outstanding, calculating Entera Bio's enterprise value requires a different approach. It uses Entera Bio's balance sheet items such as long-term debt, the book value of the preferred stock, minority interest, and other important financials.
Free Cash Flow is likely to drop to about (9.8 M) in 2022. Enterprise Value is likely to drop to about 45.7 M in 2022.
Entera Bio shows a prevailing Real Value of $4.01 per share. The current price of the firm is $1.77. Based on Macroaxis valuation methodology, the firm appears to be undervalued. Our model computes the value of Entera Bio from reviewing the firm fundamentals such as Current Valuation of 36.01 M, shares owned by institutions of 17.18 %, and Shares Owned by Insiders of 23.37 % as well as analyzing its technical indicators and Probability Of Bankruptcy. In general, we advise acquiring undervalued instruments and dropping overvalued instruments since, at some point, asset prices and their ongoing real values will submerge.
  
Entera Bio Valuation Module provides a unique way to ballpark how much the company is worth today. It is done using both, our quantitative analysis of the company fundamentals as well as its intrinsic market price estimation to project the real value. We also take into consideration other essential factors such as Entera Bio's management style, its c-level domain expertise and tenure, its overall leadership history as well as current capital structure, and future earnings potential.

Entera Most Recent Valuation Data

Price Book
2.74
EPS Estimate Next Quarter
-0.17
Price Sales
108.78
EBITDA
-13.7 M
Beta
1.99
Fiscal Year End
December
Industry
Biotechnology
Undervalued
Today 1.77
Please note that Entera Bio's price fluctuation is risky at this time. Calculation of the real value of Entera Bio is based on 3 months time horizon. Increasing Entera Bio's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Our valuation method for Entera Bio is useful when determining the fair value of the Entera stock, which is usually determined by what a typical buyer is willing to pay for full or partial control of Entera Bio. Since Entera Bio is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Entera Stock. However, Entera Bio's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value.
4.01
Real Value
9.78
Upside
Estimating the potential upside or downside of Entera Bio helps investors to forecast how Entera stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Entera Bio more accurately as focusing exclusively on Entera Bio's fundamentals will not take into account other important factors:
Earnings
Estimates (2)
LowProjected EPSHigh
-0.91-0.84-0.77
Details
Hype
Prediction
LowEstimated ValueHigh
0.091.737.50
Details
2 Analysts
Consensus
LowTarget PriceHigh
10.0011.0012.00
Details
Traditionally analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use Entera Bio's intrinsic value based on its ongoing forecasts of Entera Bio's financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against Entera Bio's closest peers. When choosing an evaluation method for Entera Bio, ensure it is appropriate for the firm given its current financial situation and market classification. If more than one evaluation category is relevant, we suggest using both methods to arrive at a better estimate.

Entera Valuation Drivers Correlation

Many accounts on the financial statements of Entera Bio are highly interrelated and sometimes correlated. Consequently, when conducting Entera's valuation analysis, one should examine all of the accounts reported to obtain a complete picture of its financial situation. We provide a unique feature to present a conventional correlation table purposely composed against different valuation-related drivers of Entera
Click cells to compare fundamentals

Entera Valuation Trend

Knowing Entera Bio's actual value is paramount for traders to make sound investment determinations. Entera Bio's real value is not only important for the investor to make better decisions but also for a more accurate overall view of Entera Bio's financial worth over time since having this information enables investors and analysts to forecast the earnings more efficiently. Using both Entera Bio's enterprise value as well as its market capitalization is the best way to gauging the value of the company and is usually enough for investors to make market timing descisions.

Entera Market Cap

Entera Bio is one of the top stocks in market capitalization category among related companies. Market capitalization of Biotechnology industry is currently estimated at about 148.32 Billion. Entera Bio adds roughly 52.39 Million in market capitalization claiming only tiny portion of stocks in Biotechnology industry.
Capitalization  Workforce  Revenue  Total debt  Valuation

Entera Bio Valuation Ratios as Compared to Competition

Comparative valuation techniques use various fundamental indicators to help in determining Entera Bio's current stock value. Our valuation model uses many indicators to compare Entera Bio value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Entera Bio competition to find correlations between indicators driving Entera Bio's intrinsic value. More Info.
Entera Bio is one of the top stocks in price to earning category among related companies. It is one of the top stocks in price to book category among related companies fabricating about  0.96  of Price to Book per Price to Earning. The ratio of Price to Earning to Price to Book for Entera Bio is roughly  1.04 . Price to Book Value is likely to rise to 3.61 in 2022. Comparative valuation analysis is a catch-all model that can be used if you cannot value Entera Bio by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Entera Bio's Stock . Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Entera Bio's earnings, one of the primary drivers of an investment's value.
Please note that valuation analysis is one of the essential comprehensive assessments in business. It evaluates Entera Bio's worth, which you can determine by considering its current assets, liabilities and future cash flows. The investors' valuation analysis is an important metric that will give you a perspective on different companies. It helps you know the worth of the potential investment in Entera Bio and how it compares across the competition.

About Entera Bio Valuation

The stock valuation mechanism determines the current worth of Entera Bio on a weekly basis. We use both absolute as well as relative valuation methodologies to arrive at the intrinsic value of Entera Bio. In general, an absolute valuation paradigm, as applied to this company, attempts to find the value of Entera Bio based exclusively on its fundamental and basic technical indicators. By analyzing Entera Bio's financials, quarterly and monthly indicators, and its related drivers such as dividends, operating cash flow, and various types of growth rates, we attempt to find the most accurate representation of Entera Bio's intrinsic value. In some cases, mostly for established, large-cap companies, we also incorporate more traditional valuation methods such as dividend discount, discounted cash flow, or asset-based models. As compared to an absolute model, our relative valuation model uses a comparative analysis of Entera Bio. We calculate exposure to Entera Bio's market risk, different technical and fundamental indicators, relevant financial multiples and ratios, and then comparing them to Entera Bio's related companies.
Fiscal Year End
December
Industry
Biotechnology
Concentration
Biotechnology
Full Time Employees
21.0
Service Category
Biotechnology
Last ReportedProjected for 2022
Gross Profit198 K187.3 K
Profit Margin(21.34) (23.03) 
Entera Bio Ltd., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of orally delivered large molecule therapeutics for unmet medical needs. Entera Bio Ltd. was incorporated in 2009 and is based in Jerusalem, Israel. Entera Bio operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 21 people.

Entera Bio Quarterly Enterprise Value

18.44 Million

Entera Bio Valuation Growth Rates

Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines. Note, investing in growth stocks can be very risky. If the company such as Entera Bio does not do well, investors take a loss on the stock when it is time to sell. Also, because growth stocks typically do not pay dividends, the only opportunity an investor has to make money on their investment is when they eventually sell their shares.
Quick Ratio8.71
Revenue Growth-56.70%
Enterprise Value To Ebitda-2.64
Enterprise Value To Revenue74.71

Entera Bio Current Valuation Indicators

Valuation refers to the process of determining the present value of Entera Bio and all of its assets. It can be calculated using a number of techniques. As many analysts who try to value Entera we look at many different elements of the entity such as Entera's management, its prospective future earnings, the current market value of the company's assets, as well as its capital structure formation. Entera Bio's valuation analysis is also a process of estimating the intrinsic value of all assets and outstanding equities. There are different methodologies and models we use to develop the final Entera Bio's valuation. The techniques such as discounted cash flow and fundamental indicators such as book value per share or market capitalization are well known and widely used across most financial advisers and money managers.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as Entera Bio, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use Entera Bio's valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes Entera Bio's worth.
Continue to Investing Opportunities. Note that the Entera Bio information on this page should be used as a complementary analysis to other Entera Bio's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Portfolio Volatility module to check portfolio volatility and analyze historical return density to properly model market risk.

Complementary Tools for Entera Stock analysis

When running Entera Bio price analysis, check to measure Entera Bio's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Entera Bio is operating at the current time. Most of Entera Bio's value examination focuses on studying past and present price action to predict the probability of Entera Bio's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Entera Bio's price. Additionally, you may evaluate how the addition of Entera Bio to your portfolios can decrease your overall portfolio volatility.
Aroon Oscillator
Analyze current equity momentum using Aroon Oscillator and other momentum ratios
Go
Money Flow Index
Determine momentum by analyzing Money Flow Index and other technical indicators
Go
Crypto Correlations
Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins
Go
Aroon Oscillator
Analyze current equity momentum using Aroon Oscillator and other momentum ratios
Go
Balance Of Power
Check stock momentum by analyzing Balance Of Power indicator and other technical ratios
Go
Portfolio Manager
State of the art Portfolio Manager to monitor and improve performance of your invested capital
Go
Portfolio Anywhere
Track or share privately all of your investments from the convenience of any device
Go
Portfolio Backtesting
Avoid under-diversification and over-optimization by backtesting your portfolios
Go
Price Transformation
Use Price Transformation models to analyze depth of different equity instruments across global markets
Go
Global Correlations
Find global opportunities by holding instruments from different markets
Go
Content Syndication
Quickly integrate customizable finance content to your own investment portal
Go
Is Entera Bio's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Entera Bio. If investors know Entera will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Entera Bio listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Market Capitalization
52.4 M
Quarterly Revenue Growth YOY
-0.57
Return On Assets
-0.42
Return On Equity
-1.0
The market value of Entera Bio is measured differently than its book value, which is the value of Entera that is recorded on the company's balance sheet. Investors also form their own opinion of Entera Bio's value that differs from its market value or its book value, called intrinsic value, which is Entera Bio's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Entera Bio's market value can be influenced by many factors that don't directly affect Entera Bio's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Entera Bio's value and its price as these two are different measures arrived at by different means. Investors typically determine Entera Bio value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Entera Bio's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.